MedPath

Comparative study of between three methods of ovulation stimulation in outcome of poor responders in ART

Phase 3
Recruiting
Conditions
Infertility.
Female infertility
Registration Number
IRCT20110908007513N17
Lead Sponsor
Esfahan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Female
Target Recruitment
150
Inclusion Criteria

Individuals with poor ovarian response in the ovulation stimulation cycle are characterized by the POSEIDON criterion. Groups 3 and 4 are entered.The third group of patients are under 35 years with abnormal ovarian reserve test AFC (number of antral follicles) less than 5 and antimullerian hormone less than 1.2 ng / cc. The fourth group of patients are over 35 years with abnormal ovarian reserve test AFC less than 5 And antimullerian hormone less than 1.2 ng / cc

Exclusion Criteria

Patients who are infected with the coronavirus during the cycle, patients who do not respond well to the ovulation stimulation cycle and do not actually have a follicle to empty, patients who received drug incorrectly during the cycle.

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Comparison of the average number of oocytes obtained and the rate of chemical pregnancy, frequency of IMPLANTATION, frequency of CILINICAL PREGNANCY, frequency of ONGOING PREGNANCY is studied in three groups. Timepoint: The time of oocyte count: after ovuum pickup, the time of positive pregnancy test: 2 weeks after embryo transfer, the time of pregnancy sac: 4 weeks after embryo transfer and the time of ongoing pregnancy rate: in 12 weeks of pregnancy. Method of measurement: Evaluation of oocyte count after ovum pickup under a microscope to evaluate pregnancy test with HCG beta titration blood test and examination of pregnancy and pregnancy sac at 12 weeks with ultrasound.
Secondary Outcome Measures
NameTimeMethod
othing. Timepoint: Nothing. Method of measurement: Nothing.
© Copyright 2025. All Rights Reserved by MedPath